- Conditions
- Healthy
- Interventions
- STSA-1005 injection, Placebo
- Drug
- Lead sponsor
- Staidson Biopharma Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 1,069
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COPD
- Interventions
- QBM076, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Chronic Kidney Disease
- Interventions
- MEDI8367, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- DX-2930, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 12
- States / cities
- San Diego, California • Walnut Creek, California • Tampa, Florida + 9 more
- Conditions
- Healthy, Safety Evaluation of Escalating Doses, Tolerability
- Interventions
- Nezavist SDD, Placebo
- Drug
- Lead sponsor
- Lohocla Research Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- COVID-19
- Interventions
- SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 12
- States / cities
- Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- MEDI7510, IIV
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 363 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Orlando, Florida • South Miami, Florida • Kansas City, Missouri + 2 more
- Conditions
- Alzheimer's Disease
- Interventions
- PU-AD, Placebo
- Drug
- Lead sponsor
- Samus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Migraine
- Interventions
- MEDI0618, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 13 more
- Conditions
- Charcot-Marie-Tooth Disease
- Interventions
- ACE-083, Placebo
- Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 16
- States / cities
- Orange, California • Aurora, Colorado • Gainesville, Florida + 13 more
- Conditions
- Healthy
- Interventions
- INX-08189 50 mg QD X 5 days, INX-08189 / Victrelis 800 mg TID X three days, Victrelis 800 mg TID x 3 days, Victrelis 800 mg TID with INX-08189 50 mg QD, Placebo with Victrelis 800 mg, Cohort 2: Victrelis 800 mg with Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Healthy Volunteers
- Interventions
- ASP1128, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Europe B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Parkinson's Disease
- Interventions
- Rasagiline, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 20 Years to 50 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- RSV Immunization
- Interventions
- RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 12 Months
- Enrollment
- 2,226 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more
- Conditions
- Cutaneous Lupus Erythematosus
- Interventions
- CC-11050, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 19
- States / cities
- Rogers, Arkansas • Los Angeles, California • San Diego, California + 15 more
- Conditions
- Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
- Interventions
- Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- GS-9450, GS-9450 Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 31
- States / cities
- Tucson, Arizona • Fresno, California • Fullerton, California + 28 more
- Conditions
- Healthy Subjects
- Interventions
- 3 g or 6 g Zidebactam, Placebo
- Drug
- Lead sponsor
- Wockhardt
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Obesity
- Interventions
- BMF-650
- Drug
- Lead sponsor
- Biomea Fusion Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Small Cell Lung Cancer
- Interventions
- Trilaciclib, Placebo, Topotecan
- Drug
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 35
- States / cities
- Hot Springs, Arkansas • Rogers, Arkansas • Corona, California + 28 more
- Conditions
- Respiratory Syncytial Viruses, Respiratory Tract Infections
- Interventions
- Ad26.RSV.preF (1*10^11 vp), Ad26.RSV.preF (5*10^10 vp), Placebo
- Biological · Drug
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 12 Months to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Newton, Kansas
- Conditions
- Gastroenteritis Escherichia Coli
- Interventions
- Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
- Drug · Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Chikungunya Virus
- Interventions
- CHIKV VLP vaccine, Placebo
- Biological
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- Fountain Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Q4W GMA301 IV injections (300 mg), Q4W GMA301 IV injections (600 mg), Q4W GMA301 IV injections (1000 mg), Q4W GMA301 IV injections (1800 mg), Q4W placebo IV injections
- Drug · Other
- Lead sponsor
- Gmax Biopharm LLC.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts